News Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Equities

600276

CNE0000014W7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23/01/2026			5-day change	1st Jan Change
58.99 ^CNY	-0.76%		-4.76%	-0.97%

01-22	Hengrui Pharmaceuticals' Subsidiaries Get Nod to Trial Two Tumor Drugs	MT
01-21	Hengrui Pharmaceuticals' Unit Gets Nod to Trial Diabetes Drugs	MT

01-22	Hengrui Pharmaceuticals' Subsidiaries Get Nod to Trial Two Tumor Drugs	MT
01-21	Hengrui Pharmaceuticals' Unit Gets Nod to Trial Diabetes Drugs	MT
01-21	Hengrui Pharmaceuticals Gets Nod to Trial Two Tumor Drugs	MT
01-20	Citigroup's long position in H shares of Jiangsu Hengrui Pharmaceuticals increases to 5.21% on Jan 14 - HKEX	RE
01-13	Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug	MT
01-13	Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation	MT
01-08	Hengrui Pharmaceuticals Wins China Marketing Approval for Gastric Cancer Drug	MT
01-07	Jiangsu Hengrui Pharmaceuticals says unit got notice from NMPA for retlirafusp alfa injection	RE
01-06	Hengrui Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Clinical Trials	MT
01-06	Hengrui Pharmaceuticals Gets Approval for Combined Obesity Drug Trials	MT
01-05	HUTCHMED Begins Phase 3 Trial of Surufatinib and Camrelizumab to Treat Pancreatic Cancer	MT
01-04	Tranche Update on Jiangsu Hengrui Pharmaceuticals Co.,Ltd's Equity Buyback Plan announced on August 20, 2025.	CI
12-30	Hengrui Pharma Gets Nod to Trial Six Drugs	MT
12-30	Hengrui Pharma Gets Nod to Trial HRS-6257 Tablets	MT
12-29	Hengrui Pharmaceuticals Licenses Kidney Drug to Hansoh Pharma in Related-Party Deal	MT
12-28	Jiangsu Hengrui Pharmaceuticals Co.,Ltd Enters into A License Agreement	CI
12-22	Jiangsu Hengrui Pharmaceuticals Co.,Ltd(SEHK:1276) added to S&P Global BMI Index	CI
12-22	Jiangsu Hengrui Pharmaceuticals Co.,Ltd(SEHK:1276) added to FTSE All-World Index	CI
12-15	JPMorgan Chase & Co's long position in H-shares of Jiangsu Hengrui Pharmaceuticals increases to 8.29%, HKEX says	RE
12-15	Hengrui Medicine's Unit Gets Nod to Trial Tumor Drug	MT
12-15	Hengrui Medicine's Unit Gets Nod to Trial RSS0343 Tablets	MT
12-15	Hengrui Medicine's Unit Gets Nod to Trial HRS9531 Injection	MT
12-12	Morgan Stanley's long position in H-shares of Jiangsu Hengrui pharmaceuticals decreases to 2.76% on Dec 8 - HKEX	RE
12-08	Hengrui Medicine's 20 Drugs Included in China's Reimbursement Drug List	MT
12-08	Jiangsu Hengrui Medicine Gets Inclusion in China's Medical Insurance Catalog	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Equities

600276

CNE0000014W7

Pharmaceuticals

Filters